Advanced search
Publication Cover
Hematology Volume 26, 2021 - Issue 1
Submit an article Journal homepage
3,267
Views
9
CrossRef citations to date
0
Altmetric
Articles

High expression of CD56 may be associated with favorable overall survival in intermediate-risk acute myeloid leukemia

Cunte Chena Institute of Hematology, School of Medicine, Key Laboratory for Regenerative Medicine of Ministry of Education, Jinan University, Guangzhou, People’s Republic of ChinaORCID Iconhttps://orcid.org/0000-0003-3733-9174View further author information
ORCID Icon,
Chi Leong Chioa Institute of Hematology, School of Medicine, Key Laboratory for Regenerative Medicine of Ministry of Education, Jinan University, Guangzhou, People’s Republic of ChinaView further author information
,
Hui Zengb Department of Hematology; First Affiliated Hospital, Jinan University, Guangzhou, People’s Republic of ChinaCorrespondence[email protected] [email protected]
View further author information
&
Yangqiu Lia Institute of Hematology, School of Medicine, Key Laboratory for Regenerative Medicine of Ministry of Education, Jinan University, Guangzhou, People’s Republic of ChinaCorrespondence[email protected] [email protected]
ORCID Iconhttps://orcid.org/0000-0002-0974-4036View further author information
ORCID Icon
Pages 210-214 | Published online: 17 Feb 2021

References

  • Lin Y, Wang Y, Zheng Y, et al. Clinical characteristics and prognostic study of adult acute myeloid leukemia patients with ASXL1 mutations. Hematology. 2020;25(1):446–456.
  • Wang K, Zhou F, Cai X, et al. Mutational landscape of patients with acute myeloid leukemia or myelodysplastic syndromes in the context of RUNX1 mutation. Hematology. 2020;25(1):211–218.
  • Yu J, Li Y, Zhang D, et al. Clinical implications of recurrent gene mutations in acute myeloid leukemia. Exp Hematol Oncol. 2020;9:4.
  • Bera R, Chiu M, Huang Y, et al. RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia. J Hematol Oncol. 2019;12(1):104.
  • Lima A, de Mello M, Fernandes E, et al. Clinical outcomes of patients with acute myeloid leukemia: evaluation of genetic and molecular findings in a real-life setting. Blood. 2015;126(15):1863–1865.
  • Chen C, Liang C, Wang S, et al. Expression patterns of immune checkpoints in acute myeloid leukemia. J Hematol Oncol. 2020;13(1):28.
  • Becker H, Marcucci G, Maharry K, et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a cancer and leukemia Group B study. J Clin Oncol. 2010;28(4):596–604.
  • Pastore F, Kling D, Hoster E, et al. Long-term follow-up of cytogenetically normal CEBPA-mutated AML. J Hematol Oncol. 2014;7:55.
  • Solovey M, Wang Y, Michel C, et al. Nuclear factor of activated T-cells, NFATC1, governs FLT3(ITD)-driven hematopoietic stem cell transformation and a poor prognosis in AML. J Hematol Oncol. 2019;12(1):72.
  • Schlenk R, Döhner K, Krauter J, et al. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358(18):1909–1918.
  • Therneau T. (2020). A Package for Survival Analysis in R. R package version 32-7, https://CRANR-projectorg/package = survival.
  • Kim N, Lee H, Lee H, et al. Natural killer cells as a promising therapeutic target for cancer immunotherapy. Arch Pharm Res. 2019;42(7):591–606.
  • Iriyama N, Hatta Y, Takeuchi J, et al. CD56 expression is an independent prognostic factor for relapse in acute myeloid leukemia with t(8;21). Leuk Res. 2013;37(9):1021–1026.
  • Montesinos P, Rayón C, Vellenga E, et al. Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens. Blood. 2011;117(6):1799–1805.
  • Coelho-Silva J, Carvalho L, Oliveira M, et al. Prognostic importance of CD56 expression in intermediate risk acute myeloid leukaemia. Br J Haematol. 2017;176(3):498–501.
  • Metzeler K, Hummel M, Bloomfield C, et al. An 86-probe-set gene-expression signature predicts survival in cytogenetically normal acute myeloid leukemia. Blood. 2008;112(10):4193–4201.
  • Chuang M, Chiu Y, Chou W, et al. An mRNA expression signature for prognostication in de novo acute myeloid leukemia patients with normal karyotype. Oncotarget. 2015;6(36):39098–39110.
  • Qin T, Wu S, Zhao H, et al. Molecular predictors of post-transplant survival in acute myeloid leukemia. Blood Cancer J. 2017;7(12):641.
  • Chen C, Wang P, Mo W, et al. Expression profile analysis of prognostic long non-coding RNA in adult acute myeloid leukemia by weighted gene co-expression network analysis (WGCNA). J Cancer. 2019;10(19):4707–4718.
  • Wang P, Fu Y, Chen Y, et al. Nomogram Personalizes and Visualizes the overall survival of patients with Triple-Negative Breast cancer based on the Immune genome. Biomed Res Int. 2020;2020:1–16.
  • Seckinger A, Meissner T, Moreaux J, et al. Clinical and prognostic role of annexin A2 in multiple myeloma. Blood. 2012;120(5):1087–1094.
  • Delgado J, Pereira A, Villamor N, et al. Survival analysis in hematologic malignancies: recommendations for clinicians. Haematologica. 2014;99(9):1410–1420.
  • Raspadori D, Damiani D, Lenoci M, et al. CD56 antigenic expression in acute myeloid leukemia identifies patients with poor clinical prognosis. Leukemia. 2001;15(8):1161–1164.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.